OverviewSuggest Edit

Elite Pharmaceuticals is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology, particularly as it relates to abuse resistant products and the manufacture of generic pharmaceuticals. The Company's strategy includes improving off-patent drug products for life cycle management, developing generic versions of controlled-release drug products with high barriers to entry and the development of branded and generic products that utilize Elite Pharmaceuticals' proprietary and patented abuse resistance technologies.

TypePublic
HQNorthvale, US
Websiteelitepharma.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Feb 2019)43
Revenue (FY, 2018)$7.5 M(-22%)

Key People/Management at Elite Pharmaceuticals

Carter Ward

Carter Ward

CFO
G. Kenneth Smith

G. Kenneth Smith

J.D., PH.D. Vice President of Legal
Chris Dick

Chris Dick

Head of Development
Show more

Elite Pharmaceuticals Office Locations

Elite Pharmaceuticals has an office in Northvale
Northvale, US (HQ)
165 Ludlow Ave
Show all (1)

Elite Pharmaceuticals Financials and Metrics

Elite Pharmaceuticals Revenue

Elite Pharmaceuticals's revenue was reported to be $7.46 m in FY, 2018
USD

Revenue (Q3, 2019)

2.7m

Gross profit (Q3, 2019)

922.8k

Gross profit margin (Q3, 2019), %

34.3%

Net income (Q3, 2019)

(2.3m)

EBIT (Q3, 2019)

(2.6m)

Market capitalization (8-Oct-2018)

68.3m

Cash (31-Dec-2018)

3.7m
Elite Pharmaceuticals's current market capitalization is $68.3 m.
Annual
USDFY, 2014FY, 2016FY, 2017FY, 2018

Revenue

4.6m12.5m9.6m7.5m

Cost of goods sold

3.2m4.5m5.9m3.5m

Gross profit

1.4m8.0m3.7m3.9m

Gross profit Margin, %

30%64%39%53%
Quarterly
USDQ2, 2014Q3, 2014Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

1.2m1.7m1.3m2.2m2.7m2.2m3.3m2.7m2.3m1.7m1.6m2.5m2.2m1.4m2.7m

Cost of goods sold

616.6k994.6k681.7k1.2m1.4m835.7k2.1m1.9m1.7m1.0m614.9k1.4m1.6m542.6k1.8m

Gross profit

542.3k698.7k574.7k966.1k1.3m1.4m1.1m834.9k603.9k687.7k1.0m1.1m591.3k820.5k922.8k

Gross profit Margin, %

47%41%46%45%48%62%34%31%26%40%62%44%27%60%34%
Annual
USDFY, 2014FY, 2016FY, 2017FY, 2018

Cash

6.9m11.5m10.6m7.2m

Accounts Receivable

732.1k1.5m

Inventories

1.9m3.3m6.4m4.9m

Current Assets

9.9m16.7m18.4m13.7m
Quarterly
USDQ2, 2014Q3, 2014Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

766.2k1.1m7.6m11.6m9.0m8.1m12.8m12.6m13.3m9.6m7.6m7.2m5.6m4.7m3.7m

Accounts Receivable

636.0k1.0m1.1m1.0m1.4m747.0k1.2m1.1m544.7k

Inventories

1.7m1.5m2.5m2.9m3.4m3.2m3.7m5.6m6.0m5.9m5.7m5.3m4.1m4.5m4.2m

Current Assets

3.3m3.9m11.7m15.8m14.1m12.4m18.0m19.7m20.6m16.4m14.6m14.8m11.5m10.4m9.4m
Annual
USDFY, 2014FY, 2016FY, 2017FY, 2018

Net Income

(96.6m)(683.0k)3.8m(3.7m)

Depreciation and Amortization

453.7k666.5k714.5k996.4k

Inventories

(574.3k)(261.7k)(3.1m)1.5m

Cash From Operating Activities

(4.2m)(2.8m)(7.9m)(4.8m)
USDY, 2018

Revenue/Employee

62.7k

Financial Leverage

-99.7 x
Show all financial metrics

Elite Pharmaceuticals News and Updates

Elite Pharmaceuticals Enters into Strategic Marketing Alliance with Lannett For Generic Adderall®

NORTHVALE, N.J., March 11, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) announced today that it has entered into a license, supply, and distribution agreement (“Agreement”) with Lannett Company, Inc. (“Lannett”).  Lannett will be the exclusive U.S. …

Elite Pharmaceuticals and SunGen Pharma Receive FDA Approval for Generic Adderall®

NORTHVALE, N.J., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the US Food and Drug Administrati…

Elite Pharmaceuticals Receives FDA Approval for Hydrocodone and Acetaminophen Combo

NORTHVALE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the U.S. Food and Drug Administr…

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2019 Ended June 30, 2018 and Provides Conference Call Information

Conference Call Scheduled for Friday, August 10th at 11:00 AM EDT Conference Call Scheduled for Friday, August 10th at 11:00 AM EDT
Show more

Elite Pharmaceuticals Frequently Asked Questions

  • Who are Elite Pharmaceuticals key executives?

    Elite Pharmaceuticals's key executives are Carter Ward, G. Kenneth Smith and Chris Dick.

  • How many employees does Elite Pharmaceuticals have?

    Elite Pharmaceuticals has 43 employees.

  • What is Elite Pharmaceuticals revenue?

    Latest Elite Pharmaceuticals annual revenue is $7.5 m.

  • What is Elite Pharmaceuticals revenue per employee?

    Latest Elite Pharmaceuticals revenue per employee is $173.5 k.

  • Who are Elite Pharmaceuticals competitors?

    Competitors of Elite Pharmaceuticals include Obsidian Therapeutics, Z Factor and Amarillo Biosciences.

  • Where is Elite Pharmaceuticals headquarters?

    Elite Pharmaceuticals headquarters is located at 165 Ludlow Ave, Northvale.

  • Where are Elite Pharmaceuticals offices?

    Elite Pharmaceuticals has an office in Northvale.

  • How many offices does Elite Pharmaceuticals have?

    Elite Pharmaceuticals has 1 office.